CLAIMS

1. An ApoCIII specific inhibitor for use in a method of i) treating, preventing, delaying or ameliorating Lipoprotein lipase deficiency (LPLD) or Familial Chylomicronemia Syndrome (FCS) in an animal; or ii) preventing, delaying or ameliorating pancreatitis, or symptom thereof in an animal with LPLD or FCS, wherein the ApoCIII specific inhibitor comprises an antisense compound targeting ApoCIII, wherein the antisense compound is an interfering RNA compound.

2. The ApoCIII specific inhibitor for use according to claim 1, wherein the interfering RNA compound is single-stranded.

3. The ApoCIII specific inhibitor for use according to claim 1, wherein the interfering RNA compound is double-stranded.

4. The ApoCIII specific inhibitor for use according to any preceding claim, wherein the interfering RNA compound is, or is at least, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to an ApoCIII nucleic acid.

5. The ApoCIII specific inhibitor for use according to claim 4, wherein the interfering RNA compound has a sequence complementary to an ApoCIII nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 4.

6. The ApoCIII specific inhibitor for use according to any preceding claim, wherein the interfering RNA compound comprises at least one modified nucleoside comprising a modified sugar moiety or at least one modified tetrahydropyran nucleoside.

7. The ApoCIII specific inhibitor for use according to any one of claims 1-5, wherein the interfering RNA compound comprises at least one modified nucleoside comprising a modified sugar moiety that comprises a substituent group selected from 2'-F and 2'-OMe, or comprises a bridge between the 4' and the 2' ribosyl ring atoms, wherein the bridge is selected from LNA and cEt.